AbbVie (ABBV) Debt to Equity (2012 - 2026)
AbbVie (ABBV) reported Debt to Equity of -$9.7 for Q1 2026, down 120.75% year-over-year from $46.71 in Q1 2025, and up 48.4% quarter-over-quarter from -$18.79 in Q4 2025.
AbbVie (ABBV) Debt to Equity (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Debt to Equity data on file, last reported at -$9.7 in Q1 2026.
- Debt to Equity for Q1 2026 came in at -$9.7, down 120.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9.7 (down 120.75% YoY), and the FY2025 annual result was -$18.79, down 194.14% from the prior year.
- Debt to Equity grew to -$9.7 in Q1 2026 per ABBV's latest filing, from -$18.79 in the prior quarter.
- Over five years, Debt to Equity peaked at $46.71 in Q1 2025 and troughed at -$470.72 in Q2 2025.
- A 5-year average of -$23.01 and a median of $4.67 in 2023 frame the typical range for Debt to Equity.
- On a YoY basis, Debt to Equity climbed as much as 489.12% in 2025 and fell as far as 4645.63% in 2025.
- A 5-year view of Debt to Equity shows it stood at $3.66 in 2022, then jumped by 56.06% to $5.71 in 2023, then jumped by 249.45% to $19.96 in 2024, then tumbled by 194.14% to -$18.79 in 2025, then jumped by 48.4% to -$9.7 in 2026.
- Business Quant data shows ABBV's Debt to Equity at -$9.7 in Q1 2026, -$18.79 in Q4 2025, and -$24.58 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.22 |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70 |
| Dec 31, 2025 | -18.79 |
| Sep 30, 2025 | -24.58 |
| Jun 30, 2025 | -470.72 |
| Mar 31, 2025 | 46.71 |
| Dec 31, 2024 | 19.96 |
| Sep 30, 2024 | 11.71 |
| Jun 30, 2024 | 10.36 |
| Mar 31, 2024 | 7.93 |
| Dec 31, 2023 | 5.71 |
| Sep 30, 2023 | 5.01 |
| Jun 30, 2023 | 4.33 |
| Mar 31, 2023 | 4.67 |
| Dec 31, 2022 | 3.66 |
| Sep 30, 2022 | 3.77 |
| Jun 30, 2022 | 4.96 |
| Mar 31, 2022 | 3.89 |
| Dec 31, 2021 | 4.97 |
| Sep 30, 2021 | 5.94 |
| Jun 30, 2021 | 6.52 |